Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study-Reference-Cited by-同舟云学术

Hospitalization and Survival in Patients Using Epoprostenol for Injection in the PROSPECT Observational Study

Published:2015-02 Issue:2 Volume:147 Page:484-494
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Frantz Robert P.,Schilz Robert J.,Chakinala Murali M.,Badesch David B.,Frost Adaani E.,McLaughlin Vallerie V.,Barst Robyn J.,Rosenberg Daniel M.,Miller Dave P.,Hartline Brian K.,Benton Wade W.,Farber Harrison W.

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference25 articles.

1. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion;Shapiro;J Am Coll Cardiol,1997

2. Primary pulmonary hypertension. A national prospective study;Rich;Ann Intern Med,1987

3. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry;Benza;Chest,2012

4. Biomarkers and surrogate endpoints in clinical trials;Fleming;Stat Med,2012

5. Evaluation of the predictive value of a clinical worsening definition using 2-year outcomes in patients with pulmonary arterial hypertension: a REVEAL Registry analysis;Frost;Chest,2013

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Geschlechterspezifische Aspekte kardiovaskulärer Erkrankungen;Die Kardiologie;2024-06-26

2. CTRP7 as a Molecular Biomarker for Predicting Responsiveness to Pulmonary Vasodilators: Insights from Human and Animal Studies in Pulmonary Arterial Hypertension;2023-11-06

3. Incidence of Bloodstream Infection in Patients with Pulmonary Hypertension under Intravenous Epoprostenol or Iloprost—A Multicentre, Retrospective Study;International Journal of Molecular Sciences;2023-03-29

4. Sex and Gender in Lung Diseases and Sleep Disorders;Chest;2023-02

5. The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States;Journal of Managed Care & Specialty Pharmacy;2022-06